Rebiotix Inc., a Ferring Company products

Rebiotix Inc., a Ferring Company, has leveraged its clinical, manufacturing and regulatory experience with RBX2660 to develop the first of its kind non-frozen, room temperature stable oral microbiota-based formulation under the MRT™ drug platform, known as RBX7455. While it is currently used to reduce the incidence of recurrent Clostridioides difficile infection, additional indications are currently under investigation.

Rebiotix Inc., a Ferring Company, has conducted several trials of the lead microbiota-based product in the MRT drug platform, RBX2660, for reducing the rate of recurrence of Clostridioides difficile infection. RBX2660 is currently under study in a Phase 3 clinical trial in conjunction with the US Food and Drug Administration’s Investigational New Drug application.

The human microbiome is defined as the microbial community (bacteria, fungi, viruses and protozoa) present in the human body. The human microbiome aids in the maintenance and development of the immune system and metabolism among other body functions. The densest and most diverse microbial community has been found in the human gastrointestinal tract. There is also increasing evidence that the gut microbiota plays an important role in protecting the host from disease. Clinical and scientific studies indicate that disturbances to the gut microbiota, often referred to as “dysbiosis,” may be involved in infectious, inflammatory, metabolic, liver and neurological diseases. Until recently, antibiotics were a common way to fight different diseases – now, the opportunity to restore gut microbes may provide an effective and durable treatment.